Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.08% is 60% above its 5-year average of 0.05%, around the middle of its 5-year range (0.00%–0.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.97% below its 12-month average of 0.10%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.08%.
DEBT TO ASSETS RATIO
0.08%
DEBT TO ASSETS RATIO AVG TTM
0.10%
DEBT TO ASSETS RATIO AVG 3Y
0.04%
DEBT TO ASSETS RATIO AVG 5Y
0.05%
DEBT TO ASSETS RATIO AVG 10Y
0.02%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-20.97%
CURRENT VS 3Y AVG
+105.47%
CURRENT VS 5Y AVG
+59.57%
CURRENT VS 10Y AVG
+227.56%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 806 covered companies
CURRENT VS SECTOR MEDIAN
-11.24%
vs the sector median at left
Monopar Therapeutics Inc.
Market Cap
$523.90M
Debt to Assets Ratio
0.08%
TTM Avg
0.10%
3Y Avg
0.04%
5Y Avg
0.05%
Market Cap
$524.71M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.11M
Debt to Assets Ratio
0.51%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.38M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.12M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$537.90M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $523.90M | 0.08% | 0.10% | 0.04% | 0.05% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.71M | 0.00% | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $515.36M | 0.07% | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $535.11M | 0.51% | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $535.38M | 0.19% | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.12M | 0.02% | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | 0.01% | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $537.90M | 0.00% | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $509.60M | 0.02% | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.52M | 0.13% | N/A | N/A | N/A |
Debt/Assets
0.1%
Debt/Equity
0.00
Current Ratio
33.56
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.08% |
| 2026-03-31 | 0.10% |
| 2025-12-31 | 0.11% |
| 2025-09-30 | 0.07% |
| 2025-06-30 | 0.15% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.06% |
| 2022-09-30 | 0.14% |
| 2022-06-30 | 0.20% |
| 2022-03-31 | 0.14% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.67% |
| 2020-06-30 | 0.96% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2016-12-31 | 0.00% |
